Peloton priced shares at $29 after the bell Wednesday, valuing the company at $8.06 billion as it prepares to make its public debut Thursday. That's at the high end of the original $26 to $29 price range Peloton was targeting. The company raised $1.16 billion in the offering.

Peloton is pitching itself to investors as more than just an at-home fitness company. With live and on-demand classes led by popular instructors, plus branded gear and clothing that members can flaunt in public, Peloton is hoping its cult-like following translates to a successful IPO.

Peloton boasts a loyal subscriber-base with over 1.4 million members that logged 55 million total workouts in fiscal 2019. In its S-1 filing, Peloton also said it had a 95 percent member retention rate which helped the company rake in $915 million in revenue. Most of that money came from sales of Peloton's high-margin and high-cost Connected Fitness Products.

The Peloton bike costs about $2,000 and its treadmill more than $4,000. The Connected Fitness Subscription, which allows members to stream classes for $39 a month, accounted for nearly 20 percent of Peloton's revenue for fiscal 2019.

Those classes are only getting more popular. Peloton says the average number of monthly workouts per connected subscriber has about doubled since the first quarter of 2017 to more than 12 workouts a month.

Still, losses for the company are widening. Peloton's annual net loss more than quintupled from $47.9 million in fiscal 2018 to $245.7 million in 2019. The company doesn't expect to achieve profitability in the near future.

Another reason that may give investors pause, Peloton is currently facing a $300 million lawsuit over the use of music streamed in its classes. The National Music Publisher's Association claims tracks from big-time artists like Taylor Swift, Adele, and the Beatles, have been used unlawfully. Peloton has spent $50.6 million on music licensing over the last three years.

Peloton will start trading Thursday on the Nasdaq Exchange under the ticker symbol PTON.

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More